MX2018009867A - Metodos que comprenden una dosificacion intermitente fija de cediranib. - Google Patents

Metodos que comprenden una dosificacion intermitente fija de cediranib.

Info

Publication number
MX2018009867A
MX2018009867A MX2018009867A MX2018009867A MX2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A
Authority
MX
Mexico
Prior art keywords
cediranib
administration
methods
composition
consecutive days
Prior art date
Application number
MX2018009867A
Other languages
English (en)
Spanish (es)
Inventor
Barry Simon
Kendrew Jane
Ho Tony
Robert Wedge Stephen
Percy Ivy Susan
KOHN Elise
Min LEE Jung-
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018009867A publication Critical patent/MX2018009867A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018009867A 2016-02-15 2017-02-14 Metodos que comprenden una dosificacion intermitente fija de cediranib. MX2018009867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Publications (1)

Publication Number Publication Date
MX2018009867A true MX2018009867A (es) 2019-05-27

Family

ID=59625551

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009867A MX2018009867A (es) 2016-02-15 2017-02-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2023007826A MX2023007826A (es) 2016-02-15 2018-08-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007826A MX2023007826A (es) 2016-02-15 2018-08-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.

Country Status (16)

Country Link
US (1) US20210322415A1 (https=)
EP (2) EP3417294B8 (https=)
JP (2) JP6865762B2 (https=)
KR (1) KR102830910B1 (https=)
CN (1) CN109073650A (https=)
AU (1) AU2017221268B2 (https=)
CA (1) CA3014674C (https=)
DK (1) DK3417294T3 (https=)
ES (1) ES2906813T3 (https=)
HU (1) HUE058114T2 (https=)
MA (1) MA44251A (https=)
MX (2) MX2018009867A (https=)
PL (1) PL3417294T3 (https=)
RU (1) RU2740849C2 (https=)
TW (1) TWI827530B (https=)
WO (1) WO2017142871A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
SG11202002499TA (en) * 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
WO2009104019A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
US20120130144A1 (en) * 2009-02-04 2012-05-24 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
TWI619704B (zh) * 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
NO2714752T3 (https=) * 2014-05-08 2018-04-21
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對pd-l1之抗體分子及其用途

Also Published As

Publication number Publication date
MA44251A (fr) 2018-12-26
KR20180125456A (ko) 2018-11-23
JP6865762B2 (ja) 2021-04-28
EP3417294B1 (en) 2021-12-01
JP2021105039A (ja) 2021-07-26
PL3417294T3 (pl) 2022-05-09
JP2019504860A (ja) 2019-02-21
ES2906813T3 (es) 2022-04-20
AU2017221268B2 (en) 2024-02-15
MX2023007826A (es) 2023-07-07
HUE058114T2 (hu) 2022-07-28
TWI827530B (zh) 2024-01-01
RU2018131377A3 (https=) 2020-06-02
AU2017221268A1 (en) 2018-08-30
US20210322415A1 (en) 2021-10-21
EP3417294A4 (en) 2019-08-14
RU2740849C2 (ru) 2021-01-21
CA3014674A1 (en) 2017-08-24
TW201906610A (zh) 2019-02-16
EP3417294A1 (en) 2018-12-26
EP4071174A1 (en) 2022-10-12
CA3014674C (en) 2024-06-18
KR102830910B1 (ko) 2025-07-04
WO2017142871A1 (en) 2017-08-24
WO2017142871A8 (en) 2018-06-14
RU2018131377A (ru) 2020-03-17
CN109073650A (zh) 2018-12-21
JP7271594B2 (ja) 2023-05-11
EP3417294B8 (en) 2022-05-04
DK3417294T3 (da) 2022-02-21

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017012991A (es) Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
BR112017011536A2 (pt) terapias de combinação
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
ECSP109969A (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
MX2018009867A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017008486A (es) Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл